T1	Participants 88 162	patients with non-small cell lung cancer not suitable for curative therapy
T2	Participants 743 895	Patients were eligible if they had stage I-IIIB NSCLC, unsuitable for curative therapy, or stage IV with a PET-detected extracranial solitary metastasis
T3	Participants 1290 1310	Eighty-four patients
